文献速递男科与性医学

1999至2014年美国男性Medicare受益人睾酮治疗趋势与模式

Trends and Patterns of Testosterone Therapy among U.S. Male Medicare Beneficiaries, 1999 to 2014.
PubMed 文献 · J Urol · 2020-01-13

该研究基于Medicare数据库(1999-2014)评估老年美国男性睾酮治疗模式,估算年龄标化发病率和患病率。期间共392,698例新使用者,2007-2014年平均年百分比变化15.5%,2014年下降;2014年最常见潜在指征为性腺功能减退(48%),而治疗前睾酮检测率低(35%至少1次,4%推荐2次)。

要点

  • 睾酮治疗在老年美国男性中常见,2007-2014年平均年增长15.5%,2014年下降。
  • 2014年最常见指征为性腺功能减退(48%),但疲劳(18%)等非特异指征占相当比例。
  • 治疗前睾酮检测不足:仅35%在120天内至少1次,4%完成推荐2次检测。

核心结论

  • 睾酮治疗在老年美国男性中仍常见,尽管近期下降;处方主要针对性腺功能减退,但相当比例用于非特异症状,且睾酮检测不频繁。

主要发现

  • 睾酮治疗使用者以较年轻、非西班牙裔白人为主,多位于美国南部和西部 census 区域。
  • 2007至2014年平均年百分比变化为15.5%,但2014年出现下降。
  • 2014年记录的潜在指征包括性腺功能减退(48%)、疲劳(18%)、勃起功能障碍(15%)、抑郁(4%)和精神性功能障碍(1%)。
  • 治疗前120天内仅35%至少进行1次睾酮检测,4%完成推荐的2次治疗前检测,16%至少1次治疗前和1次治疗后检测。

临床怎么用

  • 临床医生应严格评估睾酮治疗指征,优先用于确诊性腺功能减退者,避免仅基于非特异症状处方。
  • 处方睾酮前应遵循推荐进行睾酮水平检测(如2次治疗前检测),并在治疗中监测。

局限性

  • 研究基于Medicare行政数据,潜在指征依赖记录代码,可能不完整或存在误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We explored the Medicare database (1999 to 2014) to provide a comprehensive assessment of testosterone therapy patterns in the older U.S. male population. MATERIALS AND METHODS: We estimated annual age-standardized incidence (new users) and prevalence (existing users) of testosterone therapy according to demographic characteristics, comorbidities and potential indications. RESULTS: There were 392,698 incident testosterone therapy users during 88 million person-years. Testosterone therapy users were predominantly younger, white nonHispanic, and located in South and West U.S. Census regions. On average testosterone therapy use increased dramatically during 2007 to 2014 (average annual percent change 15.5%), despite a decrease in 2014. In 2014 the most common recorded potential indications for any testosterone therapy were hypogonadism (48%), fatigue (18%), erectile dysfunction (15%), depression (4%) and psychosexual dysfunction (1%). Laboratory tests to measure circulating testosterone concentrations for testosterone therapy were infrequent with 35% having had at least 1 testosterone test in the 120 days preceding testosterone therapy, 4% the recommended 2 pre-testosterone therapy tests, and 16% at least 1 pre-testosterone therapy test and at least 1 post-testosterone therapy test. CONCLUSIONS: Testosterone therapy remains common in the older U.S. male population, despite a recent decrease. Although testosterone therapy prescriptions are predominantly for hypogonadism, a substantial proportion appear to be for less specific conditions. Testosterone tests among men prescribed testosterone therapy appear to be infrequent.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Zhou CK, Advani S, Chaloux M, et al. Trends and Patterns of Testosterone Therapy among U.S. Male Medicare Beneficiaries, 1999 to 2014. J Urol. 2020. PMID: 31928462. doi:10.1097/JU.0000000000000744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。